|
|
|
|
|
|
The CPHI Annual Report 2023 that was released last month includes insights from 250 global pharma companies and predicts that “within 10 years, over 50% of approved drugs will involve AI in their development and/or manufacturing.” |
|
|
|
As investment in the life sciences industry decreases, young companies struggle to keep the lights on. Young companies may overcome these challenges by implementing operational excellence (OpEx) early on in drug development rather than waiting until manufacturing start-up. |
|
|
|
In ISR’s inaugural Gene Therapy CDMO Benchmarking Report, we asked respondents to identify the stage in which their company would typically engage a CDMO to support their gene therapy manufacturing needs. |
|
|
|
|
|
|
Inside you will find more on: - Top Executive Interviews
- Companies To Watch
- Hiring Strategies
- Risk Mitigation
View the digital edition. |
|
|
CONTRIBUTE TO LIFE SCIENCE LEADER |
|
|
|
Think you have a good idea for an article that Life Science Leader readers would find valuable? Read these guidelines first before submitting your idea or your article to our editorial director. |
|
|
| Connect With Life Science Leader: |
|
|
|
